Oncolytics Biotech (ONCY) Institutional Ownership $0.73 -0.01 (-1.79%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.74 +0.01 (+1.98%) As of 02/21/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Oncolytics Biotech (NASDAQ:ONCY)CurrentInstitutional OwnershipPercentage6.82%Number ofInstitutional Buyers(last 12 months)5TotalInstitutional Inflows(last 12 months)$258.06KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$20.96K Get ONCY Insider Trade Alerts Want to know when executives and insiders are buying or selling Oncolytics Biotech stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ONCY Institutional Buying and Selling by Quarter Oncolytics Biotech Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/12/2025 Geode Capital Management LLC66,939$61K0.0%+59.6%0.084% 2/12/2025 National Bank of Canada FI64,479$60K0.0%+199.6%0.081% 2/11/2025 Virtu Financial LLC98,452$90K0.0%N/A0.123% 1/24/2025 Vantage Point Financial LLC29,744$27K0.0%N/A0.037% 1/8/2025 International Assets Investment Management LLC200,400$186K0.0%+15.0%0.259% 10/22/2024 International Assets Investment Management LLC174,331$152K0.0%-12.1%0.228% 5/20/2024 Virtu Financial LLC51,889$55K0.0%N/A0.068% 1/24/2024 International Assets Investment Management LLC269,699$364K0.0%+33.9%0.362% 1/12/2024Advisor Resource Council100,000$135K0.0%N/A0.134% 1/11/2024 Ausdal Financial Partners Inc.30,000$40K0.0%+50.0%0.041% Get the Latest News and Ratings for ONCY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. 11/8/2023 Ausdal Financial Partners Inc.20,000$44K0.0%N/A0.027% 10/13/2023 Brave Asset Management Inc.25,000$55K0.0%+150.0%0.035% 10/10/2023 International Assets Investment Management LLC201,453$449K0.0%+3.3%0.278% 10/4/2023 International Assets Investment Management LLC201,453$449K0.0%+3.3%0.278% 8/23/2023 Headinvest LLC11,534$30K0.0%N/A0.016% 8/2/2023 Bank of Montreal Can32,380$85K0.0%N/A0.049% 7/24/2023 Brave Asset Management Inc.10,000$26K0.0%N/A0.015% 7/20/2023 International Assets Investment Management LLC194,963$507K0.1%+3.4%0.297% 2/7/2023Lynwood Capital Management Inc.25,000$41K0.0%N/A0.041% 1/24/2023 International Assets Investment Management LLC169,111$609K0.1%-6.9%0.276% 1/20/2023 Newman Dignan & Sheerar Inc.18,915$31K0.0%+46.5%0.031% 8/11/2022 Toronto Dominion Bank35,362$34K0.0%N/A0.061% 7/27/2022Advisor Resource Council100,000$101K0.0%N/A0.173% 2/14/2022 Long Focus Capital Management LLC40,000$56K0.0%N/A0.073% 2/11/2022Advisor Resource Council100,000$139K0.0%N/A0.182% 11/12/2021 Renaissance Technologies LLC209,900$439K0.0%+812.6%0.382% 10/28/2021 International Assets Investment Management LLC170,576$357K0.1%+5.4%0.310% 10/7/2021 Newman Dignan & Sheerar Inc.12,915$27K0.0%N/A0.023% 9/17/2021 Virtu Financial LLC35,425$98K0.0%N/A0.064% 8/19/2021Advisor Resource Council101,000$280K0.0%N/A0.184% 8/13/2021 Renaissance Technologies LLC23,000$64K0.0%N/A0.042% 8/12/2021 JPMorgan Chase & Co.150,673$919K0.0%+167.7%0.274% 8/12/2021 Bank of Montreal Can16,460$46K0.0%+40.1%0.030% 7/31/2021 Brave Asset Management Inc.20,000$55K0.0%+100.0%0.036% 5/21/2021 Citadel Advisors LLC49,378$188K0.0%N/A0.093% 5/19/2021 Chiron Capital Management LLC10,000$38K0.0%N/A0.019% 5/19/2021 Squarepoint Ops LLC11,650$44K0.0%N/A0.022% 5/18/2021 Citadel Advisors LLC49,378$188K0.0%N/A0.093% 5/17/2021 Royal Bank of Canada27,381$105K0.0%-23.0%0.052% 5/17/2021 Goldman Sachs Group Inc.10,300$39K0.0%N/A0.019% Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry." (Ad)If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.You MUST act before March 17th.5/12/2021 Geode Capital Management LLC24,545$92K0.0%+51.4%0.046% 5/12/2021 JPMorgan Chase & Co.56,283$214K0.0%N/A0.107% 5/11/2021 Toronto Dominion Bank22,465$85K0.0%+190.5%0.043% 5/11/2021Banque Cantonale Vaudoise11,268$42K0.0%+723.7%0.021% 4/26/2021 Brave Asset Management Inc.10,000$38K0.0%N/A0.019% 4/19/2021 International Assets Investment Management LLC277,852$885K0.1%+130.1%0.533% 2/24/2021 Virtu Financial LLC19,587$47K0.0%N/A0.047% 2/10/2021 Renaissance Technologies LLC174,220$415K0.0%+1,284.3%0.418% (Data available from 1/1/2016 forward) ONCY Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ONCY shares? During the previous two years, 10 institutional investors and hedge funds held shares of Oncolytics Biotech. The most heavily invested institutionals were International Assets Investment Management LLC ($186K), Advisor Resource Council ($135K), Virtu Financial LLC ($90K), Bank of Montreal Can ($85K), Geode Capital Management LLC ($61K), National Bank of Canada FI ($60K), and Brave Asset Management Inc. ($55K).Learn more on ONCY's institutional investors. What percentage of Oncolytics Biotech stock is owned by institutional investors? 6.82% of Oncolytics Biotech stock is owned by institutional investors. Learn more on ONCY's institutional investor holdings. Which institutional investors have been buying Oncolytics Biotech stock? Of the 10 institutional investors that purchased Oncolytics Biotech stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Virtu Financial LLC ($150.34K), International Assets Investment Management LLC ($113.64K), Advisor Resource Council ($100K), National Bank of Canada FI ($42.96K), Bank of Montreal Can ($32.38K), Ausdal Financial Partners Inc. ($30K), and Vantage Point Financial LLC ($29.74K). How much institutional buying is happening at Oncolytics Biotech? Institutional investors have bought a total of 560,586 shares in the last 24 months. This purchase volume represents approximately $759.95K in transactions. Which Oncolytics Biotech major shareholders have been selling company stock? The following institutional investors have sold Oncolytics Biotech stock in the last 24 months: International Assets Investment Management LLC ($24.07K). How much institutional selling is happening at Oncolytics Biotech? Institutional investors have sold a total of 24,069 shares in the last 24 months. This volume of shares sold represents approximately $20.96K in transactions. Related Companies LifeVantage Institutional Ownership Voyager Therapeutics Institutional Ownership Design Therapeutics Institutional Ownership 4D Molecular Therapeutics Institutional Ownership Lifecore Biomedical Institutional Ownership C4 Therapeutics Institutional Ownership Cardiff Oncology Institutional Ownership Acelyrin Institutional Ownership Larimar Therapeutics Institutional Ownership Ocugen Institutional Ownership This page (NASDAQ:ONCY) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
